Lansoprazol Krka 30 mg Norge - norsk - Statens legemiddelverk

lansoprazol krka 30 mg

krka sverige ab - lansoprazol - enterokapsel, hard - 30 mg

Lansoprazol Krka 15 mg Norge - norsk - Statens legemiddelverk

lansoprazol krka 15 mg

krka sverige ab - lansoprazol - enterokapsel, hard - 15 mg

Lansoprazol Medical Valley 30 mg Norge - norsk - Statens legemiddelverk

lansoprazol medical valley 30 mg

medical valley invest ab - lansoprazol - enterokapsel, hard - 30 mg

Lansoprazol Medical Valley 15 mg Norge - norsk - Statens legemiddelverk

lansoprazol medical valley 15 mg

medical valley invest ab - lansoprazol - enterokapsel, hard - 15 mg

Lansoprazol Pensa 30 mg Norge - norsk - Statens legemiddelverk

lansoprazol pensa 30 mg

pensa pharma ab - lansoprazol - enterokapsel, hard - 30 mg

Lansoprazol Pensa 15 mg Norge - norsk - Statens legemiddelverk

lansoprazol pensa 15 mg

pensa pharma ab - lansoprazol - enterokapsel, hard - 15 mg

Lanzo Melt 30 mg Norge - norsk - Statens legemiddelverk

lanzo melt 30 mg

pfizer as - lansoprazol - smeltetablett - 30 mg

Lanzo Melt 15 mg Norge - norsk - Statens legemiddelverk

lanzo melt 15 mg

pfizer as - lansoprazol - smeltetablett - 15 mg

Lumykras Den europeiske union - norsk - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karsinom, ikke-småcellet lunge - antineoplastiske midler - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Clopidogrel Acino Den europeiske union - norsk - EMA (European Medicines Agency)

clopidogrel acino

acino ag - klopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.